http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 Aug 2025 07:30:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html <p>HONG KONG, Aug 20, 2025 - (JCN Newswire) - - During 1H2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China&apos;s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; &apos;CanSinoBIO&apos;) once again delivered a solid performance.</p><p>According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html Wed, 20 Aug 2025 07:30:00 -0500 6185 688185 CASBF O.28057839 http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html <p>HONG KONG, Aug 20, 2025 - (JCN Newswire) - - During 1H2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China&apos;s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; &apos;CanSinoBIO&apos;) once again delivered a solid performance.</p><p>According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html Wed, 20 Aug 2025 07:30:00 -0500 6185 688185 CASBF O.28057839 http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html <p>HONG KONG, Aug 20, 2025 - (JCN Newswire) - - During 1H2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China&apos;s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; &apos;CanSinoBIO&apos;) once again delivered a solid performance.</p><p>According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html Wed, 20 Aug 2025 07:30:00 -0500 6185 688185 CASBF O.28057839 http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html <p>HONG KONG, Aug 20, 2025 - (JCN Newswire) - - During 1H2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China&apos;s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; &apos;CanSinoBIO&apos;) once again delivered a solid performance.</p><p>According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, http://www.streetinsider.com/Press+Releases/Innovative+Vaccine+Engine+Continues+to+Drive+Growth%3A+CanSinoBIO+Enters+a+New+Growth+Cycle/25231539.html Wed, 20 Aug 2025 07:30:00 -0500 6185 688185 CASBF O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html <p>HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide.</p><p>According to the World Health Organization(WHO), pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. Notably, in China, non-invasive pneumococcal diseases(NIPD), result in approximately 550,000 cases annually, leading to around 6,000 deaths. Meanwhile, invasive pneumococcal diseases (IPD) are more severe, http://www.streetinsider.com/Press+Releases/CanSinoBIO+Launches+Pneumococcal+Vaccine%3A+An+Innovative+Choice+to+Safeguard+Children%26apos%3Bs+Health/24957949.html Fri, 20 Jun 2025 05:06:00 -0500 6185 688185 A.17568957 CASBF O.04889877 O.28057839 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html <p>HONG KONG, Mar 25, 2025 - (JCN Newswire) - - CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, &apos;CanSinoBIO&apos; or the &apos;Company&apos;), a leading player in China&apos;s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&amp;D innovation and strong commercial capabilities.</p><p>In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company&apos;s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for http://www.streetinsider.com/Press+Releases/Revenue+Soars+with+137%25+Year-on-Year+Growth%2C+Multiple+Products+Poised+for+Launch%2C+CanSinoBIO%26apos%3Bs+Growth+Momentum+Strong/24545990.html Tue, 25 Mar 2025 10:34:00 -0500 6185 A.17568957 A.17608877 A.35846118 A.50210054 CASBF O.00018297 O.04889877 O.23706255 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html <p>HONG KONG, Oct 9, 2024 - (ACN Newswire) - - CanSino Biologics Inc. (&quot;CanSinoBIO&quot; or &quot;the Company&quot;) has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine (&quot;VLP-Polio&quot;) project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.</p><p>In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html Wed, 09 Oct 2024 06:29:00 -0500 6185 688185 A.17568957 A.17608877 CASBF CJH O.04889877 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html <p>HONG KONG, Oct 9, 2024 - (ACN Newswire) - - CanSino Biologics Inc. (&quot;CanSinoBIO&quot; or &quot;the Company&quot;) has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine (&quot;VLP-Polio&quot;) project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.</p><p>In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html Wed, 09 Oct 2024 06:29:00 -0500 6185 688185 A.17568957 A.17608877 CASBF CJH O.04889877 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html <p>HONG KONG, Oct 9, 2024 - (ACN Newswire) - - CanSino Biologics Inc. (&quot;CanSinoBIO&quot; or &quot;the Company&quot;) has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine (&quot;VLP-Polio&quot;) project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.</p><p>In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html Wed, 09 Oct 2024 06:29:00 -0500 6185 688185 A.17568957 A.17608877 CASBF CJH O.04889877 O.28057839 O.37000441 http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html <p>HONG KONG, Oct 9, 2024 - (ACN Newswire) - - CanSino Biologics Inc. (&quot;CanSinoBIO&quot; or &quot;the Company&quot;) has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine (&quot;VLP-Polio&quot;) project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.</p><p>In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This http://www.streetinsider.com/Press+Releases/CanSino+Receives+Another+Strong+Boost/23818289.html Wed, 09 Oct 2024 06:29:00 -0500 6185 688185 A.17568957 A.17608877 CASBF CJH O.04889877 O.28057839 O.37000441